• Latest
  • Trending
  • All
  • Egypt
  • Business
  • Local
  • World
COVID rebound after Pfizer treatment likely due to robust immune response

COVID rebound after Pfizer treatment likely due to robust immune response

October 7, 2022
Egypt denounces drone attacks on Khartoum, UN building

Egypt denounces drone attacks on Khartoum, UN building

November 22, 2026
Egypt condemns attempted missile attacks on Saudi cities

Egypt condemns attack on Benghazi port

November 22, 2026
Leaders at UN climate talks discuss why negotiations ended without deal

Leaders at UN climate talks discuss why negotiations ended without deal

November 22, 2026
Abdelatty, Iraqi counterpart probe bilateral ties, regional developments

Abdelatty, Iraqi counterpart probe bilateral ties, regional developments

November 22, 2026
‘Egyptian crew repels 3 piracy attempts against cargo ship in Gulf of Aden’

‘Egyptian crew repels 3 piracy attempts against cargo ship in Gulf of Aden’

November 22, 2026
US intelligence chief predicts more tech outages

US intelligence chief predicts more tech outages

November 22, 2026
Salah features as Trabzonspor edge past Eyupspor

Salah features as Trabzonspor edge past Eyupspor

November 22, 2026
Liverpool thrash 10-man United 4-0

Liverpool thrash 10-man United 4-0

November 22, 2026
Egypt, WB mull economic reforms, development financing

Egypt, WB mull economic reforms, development financing

November 22, 2026
Egypt U17 beat Qatar to secure first World Cup win

Egypt U17 beat Qatar to secure first World Cup win

November 22, 2026
  • Advertise
  • Privacy & Policy
  • Contact
Monday, November 23, 2026
  • Login

Editor-in-Chief

Mohamed Fahmy

Board Chairman

Tarek Lotfy

Egyptian Gazette
No Result
View All Result
  • HOME
  • EGYPT
    • Local
    • Features
  • World
    • National Day
  • Technology
  • BUSINESS
    • Real Estate
    • Automotive
  • SPORTS
  • ENTERTAINMENT
    • Arts
    • Health
    • Lifestyle
    • Travel
    • Tourism
    • Odd News
  • Skyward
    • Snippets from EgyptAir history
  • MORE
    • Multimedia
      • Video
      • Podcast
      • Gallery
    • OP-ED
  • HOME
  • EGYPT
    • Local
    • Features
  • World
    • National Day
  • Technology
  • BUSINESS
    • Real Estate
    • Automotive
  • SPORTS
  • ENTERTAINMENT
    • Arts
    • Health
    • Lifestyle
    • Travel
    • Tourism
    • Odd News
  • Skyward
    • Snippets from EgyptAir history
  • MORE
    • Multimedia
      • Video
      • Podcast
      • Gallery
    • OP-ED
No Result
View All Result
Egyptian Gazette
Home Entertainment Health

COVID rebound after Pfizer treatment likely due to robust immune response

by News Wires
October 7, 2022
in Health
A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one.

A rebound of COVID-19 symptoms in some patients after taking Pfizer's antiviral Paxlovid may be related to a robust immune response rather than a weak one.

Share on FacebookWhatsapp

CHICAGO – A rebound of COVID-19 symptoms in some patients after taking Pfizer’s antiviral Paxlovid may be related to a robust immune response rather than a weak one, US government researchers reported.

They concluded that taking a longer course of the drug – beyond the recommended five days – was not required to reduce the risk of a recurrence of symptoms as some have suggested, based on an intensive investigation of rebound in eight patients at the National Institutes of Health’s Clinical Center.

All patients in the study had developed robust immune responses, but researchers found higher levels of antibodies in the patients who experienced a rebound.

The team said their data argues against the hypothesis that impaired immune responses are the reason symptoms return in some patients.

“Our findings suggest that a more robust immune response rather than uncontrolled viral replication characterizes these clinical rebounds,” the team wrote according to Reuters.

The study, published in the journal Clinical Infectious Diseases, followed numerous reports of individuals who took Paxlovid as recommended within five days of infection and saw a return of symptoms after they completed the five-day course of treatment.

President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci both experienced a COVID rebound after taking the medicine.

The cases raised concerns that Pfizer’s two-drug antiviral treatment could interfere with development of a long-lasting immune response.

The study involved six people whose COVID symptoms returned after taking Paxlovid, and two with rebound symptoms after apparent recovery who did not take the pills.

Their responses were compared to a group of six people who had COVID but did not experience a rebound. All volunteers had been vaccinated and boosted and all were infected with some version of the Omicron variant of the virus.

Blood from study volunteers underwent intensive investigation to assess their immune response during the acute infection phase and the rebound phase.

All of the rebound patients had experienced significant improvement in their symptoms before their rebound. Of those who had a rebound after Paxlovid, four had milder symptoms than during their initial infection, one had the same level of severity and one reported worse symptoms.

None of the rebound patients required additional treatment or hospitalization.

Rebound symptoms may be partially driven by a robust immune response to residual virus in the respiratory tract, the study authors suggested. They concluded that the drug does not impede the immune response in some individuals, as some had feared.

Larger and more detailed studies are needed to further understand COVID symptom rebound, the research team said, adding that the current data supports the need for isolation of such patients.

The researchers also suggested that there is still a need to evaluate longer courses of Paxlovid in immunocompromised individuals where the immune response may be ineffective.

Tags: Covid-19HealthPaxlovidPfizerUSA

Discussion about this post

ADVERTISEMENT
egyptian-gazette-logo

The Egyptian Gazette is the oldest English-language daily newspaper in the Middle East.
It was first published on January 26, 1880 and it is part of El Tahrir Printing and Publishing House.

Follow Us

Egypt denounces drone attacks on Khartoum, UN building

Egypt condemns attack on Benghazi port

Leaders at UN climate talks discuss why negotiations ended without deal

Abdelatty, Iraqi counterpart probe bilateral ties, regional developments

‘Egyptian crew repels 3 piracy attempts against cargo ship in Gulf of Aden’

  • Advertise
  • Privacy & Policy
  • Contact

Copyrights for © Egyptian Gazette - Administered by Digital Transformation Management.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • EGYPT
    • Local
    • Features
  • World
    • National Day
  • Technology
  • BUSINESS
    • Real Estate
    • Automotive
  • SPORTS
  • ENTERTAINMENT
    • Arts
    • Health
    • Lifestyle
    • Travel
    • Tourism
    • Odd News
  • Skyward
    • Snippets from EgyptAir history
  • MORE
    • Multimedia
      • Video
      • Podcast
      • Gallery
    • OP-ED

Copyrights for © Egyptian Gazette - Administered by Digital Transformation Management.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.